NO952884L - Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler - Google Patents

Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler

Info

Publication number
NO952884L
NO952884L NO952884A NO952884A NO952884L NO 952884 L NO952884 L NO 952884L NO 952884 A NO952884 A NO 952884A NO 952884 A NO952884 A NO 952884A NO 952884 L NO952884 L NO 952884L
Authority
NO
Norway
Prior art keywords
optionally
alkenylene
sum
substituted
image
Prior art date
Application number
NO952884A
Other languages
English (en)
Norwegian (no)
Other versions
NO952884D0 (no
Inventor
Sundeep Dugar
John W Clader
Duane A Burnett
Margaret Browne
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO952884D0 publication Critical patent/NO952884D0/no
Publication of NO952884L publication Critical patent/NO952884L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO952884A 1993-01-21 1995-07-20 Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler NO952884L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US643993A 1993-01-21 1993-01-21
PCT/US1994/000421 WO1994017038A1 (fr) 1993-01-21 1994-01-19 Azetidinones a substitution spirocycloalkyle utilisees comme agents hypocholesterolemiques

Publications (2)

Publication Number Publication Date
NO952884D0 NO952884D0 (no) 1995-07-20
NO952884L true NO952884L (no) 1995-09-20

Family

ID=21720894

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952884A NO952884L (no) 1993-01-21 1995-07-20 Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler

Country Status (26)

Country Link
US (1) US5698548A (fr)
EP (1) EP0681569B1 (fr)
JP (1) JP2719445B2 (fr)
KR (1) KR960700227A (fr)
CN (1) CN1118163A (fr)
AT (1) ATE199899T1 (fr)
AU (1) AU683048B2 (fr)
CA (1) CA2154257C (fr)
CZ (1) CZ180195A3 (fr)
DE (1) DE69426924T2 (fr)
DK (1) DK0681569T3 (fr)
EE (1) EE9400394A (fr)
ES (1) ES2155849T3 (fr)
FI (1) FI953497A (fr)
GR (1) GR3035963T3 (fr)
HU (1) HUT72592A (fr)
IL (1) IL108368A0 (fr)
LT (1) LT3595B (fr)
NO (1) NO952884L (fr)
NZ (1) NZ261714A (fr)
PL (1) PL309978A1 (fr)
PT (1) PT681569E (fr)
SI (1) SI9400022A (fr)
SK (1) SK91195A3 (fr)
WO (1) WO1994017038A1 (fr)
ZA (1) ZA94386B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK158394A3 (en) * 1992-06-26 1995-05-10 Pfizer Steroidal glycosides
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5648484A (en) * 1995-03-07 1997-07-15 Schering Corporation Catalytic enantioselective synthesis of a spriofused azetidinone
GEP20033006B (en) * 1995-10-31 2003-07-10 Schering Corp Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
DE60106489T2 (de) * 2000-12-20 2005-10-13 Schering Corp. Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
US7417039B2 (en) * 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2434504A1 (fr) * 2001-01-26 2002-08-01 Teddy Kosoglou Combinaisons d'inhibiteur(s) de l'absorption des sterols et de modificateurs sanguins pour le traitement de troubles vasculaires
CA2442219C (fr) 2001-03-28 2007-09-11 Schering Corporation Synthese enantioselective de composes intermediaires d'azetidinone
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
SI1429756T1 (sl) * 2001-09-21 2007-02-28 Schering Corp Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
DE60334711D1 (de) 2002-07-30 2010-12-09 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
ATE406364T1 (de) * 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
PL1622569T3 (pl) 2003-04-24 2016-06-30 Incyte Holdings Corp Pochodne aza spiro alkanów jako inhibitory metaloproteaz
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1918000A2 (fr) 2003-11-05 2008-05-07 Schering Corporation Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CN100471835C (zh) * 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
BRPI0418004A (pt) 2003-12-23 2007-04-17 Astrazeneca Ab composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
US20080281094A1 (en) * 2004-05-10 2008-11-13 Laboratorios Del Dr. Esteve, S.A. Regioselective Functionalisation and Protection of Spirolactams
EP1676836A1 (fr) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Hydroxylation, fonctionnalisation et protection regioselective de spirolactames
US20080045726A1 (en) * 2004-05-10 2008-02-21 Laboratorios Del Dr. Esteve, S.A. Spirolactams and Their Synthesis
EP1598336A1 (fr) * 2004-05-20 2005-11-23 Laboratorios Del Dr. Esteve, S.A. Hydroxylation, fonctionnalisation et protection regioselective de spirolactames
US7291728B2 (en) 2004-05-10 2007-11-06 Laboratories Del Dr. Esteve, S.A. Spirolactams and their synthesis
EP1807070A1 (fr) * 2004-09-29 2007-07-18 Schering Corporation Combinaisons d'azetidinones substituees et d'antagonistes cb1
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
US8361999B2 (en) 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
ES2337727T3 (es) * 2005-06-20 2010-04-28 Schering Corporation Derivados de piperidina utiles como antagonistas de histamina h3.
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MX2008008340A (es) * 2005-12-21 2008-09-03 Schering Corp Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
CA2637565A1 (fr) 2006-01-18 2007-07-26 Schering Corporation Modulateurs de recepteurs de cannibinoides
WO2007100807A2 (fr) 2006-02-24 2007-09-07 Schering Corporation Orthologues de npc1l1
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CA2661404A1 (fr) * 2006-09-05 2008-03-13 Schering Corporation Compositions pharmaceutiques pour un traitement des lipides et dans le traitement de l'atherosclerose et de la steatose hepatique
CA2663947A1 (fr) * 2006-09-15 2008-03-20 Schering Corporation Derives d'azetidine et d'azetidone convenant dans le traitement de la douleur et des troubles du metabolisme des lipides
AR062790A1 (es) 2006-09-15 2008-12-03 Schering Corp Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos
CA2663502A1 (fr) * 2006-09-15 2008-03-20 Schering Corporation Derives d'azetidinone et procedes d'utilisation de ceux-ci
CA2663503A1 (fr) * 2006-09-15 2008-03-20 Schering Corporation Derives d'azetidinone et procedes d'utilisation de ceux-ci
WO2008033431A1 (fr) * 2006-09-15 2008-03-20 Schering Corporation Dérivés d'azétidinone spirocyclique traitant les troubles du métabolisme des lipides, la douleur, le diabète et d'autres troubles
MX2009002920A (es) * 2006-09-15 2009-04-01 Schering Corp Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
US7902157B2 (en) 2006-09-15 2011-03-08 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
EP2548874A3 (fr) 2007-06-28 2013-05-15 Intervet International B.V. Pipérazines substituées utilisées en tant qu'antagonistes CB1
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
CA2754384A1 (fr) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Compositions pharmaceutiques hypocholesterolemiques
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
PT2547679E (pt) 2010-03-19 2016-01-27 Pfizer Derivados de 2,3-di-hidro-1h-indeno-1-il-2,7-diazaspiro[3.6]nonano e sua utilização como antagonistas ou agonistas inversos do receptor de grelina
MX365046B (es) 2012-05-01 2019-05-17 Althera Life Sciencies Llc Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
CN104496838B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
WO2020104930A1 (fr) 2018-11-20 2020-05-28 Piramal Enterprises Limited Synthèse asymétrique améliorée de composés azaspiro
EP3942047A1 (fr) 2019-03-20 2022-01-26 Regeneron Pharmaceuticals, Inc. Traitement de niveaux de lipides accrus avec des inhibiteurs de protéine d'activation de clivage de protéine de liaison d'élément régulateur de stérol (scap)
EP3942048A1 (fr) 2019-03-20 2022-01-26 Regeneron Pharmaceuticals, Inc. Traitement de niveaux de lipides accrus avec des inhibiteurs du facteur de transcription 1 de liaison à un élément régulateur de stérol (srebf1)
TW202340202A (zh) * 2021-12-22 2023-10-16 美國加利福尼亞大學董事會 Gtp酶抑制劑及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2048080C3 (de) * 1970-09-30 1979-11-29 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
US4692515A (en) * 1984-09-24 1987-09-08 Pennwalt Corporation Adamantane-spirolactams
NZ228600A (en) 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5130425A (en) * 1990-10-12 1992-07-14 American Home Products Corporation Spiro-lactams and analogs thereof useful as aldose reductase inhibitors
HUT67341A (en) * 1991-07-23 1995-03-28 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof

Also Published As

Publication number Publication date
AU683048B2 (en) 1997-10-30
EP0681569B1 (fr) 2001-03-21
JP2719445B2 (ja) 1998-02-25
ES2155849T3 (es) 2001-06-01
JPH08501110A (ja) 1996-02-06
DE69426924T2 (de) 2001-08-16
DE69426924D1 (de) 2001-04-26
HU9502194D0 (en) 1995-09-28
EP0681569A1 (fr) 1995-11-15
WO1994017038A1 (fr) 1994-08-04
SK91195A3 (en) 1995-12-06
CN1118163A (zh) 1996-03-06
ATE199899T1 (de) 2001-04-15
CA2154257C (fr) 1999-05-25
LT3595B (en) 1995-12-27
ZA94386B (en) 1994-07-19
PT681569E (pt) 2001-06-29
LTIP1764A (en) 1995-02-27
GR3035963T3 (en) 2001-08-31
CA2154257A1 (fr) 1994-08-04
DK0681569T3 (da) 2001-04-23
FI953497A0 (fi) 1995-07-20
KR960700227A (ko) 1996-01-19
HUT72592A (en) 1996-05-28
PL309978A1 (en) 1995-11-13
EE9400394A (et) 1996-06-17
FI953497A (fi) 1995-07-20
AU6087294A (en) 1994-08-15
US5698548A (en) 1997-12-16
IL108368A0 (en) 1994-04-12
NZ261714A (en) 1997-02-24
NO952884D0 (no) 1995-07-20
SI9400022A (en) 1995-02-28
CZ180195A3 (en) 1996-01-17

Similar Documents

Publication Publication Date Title
NO952884D0 (no) Spirocykloalkyl-substituerte azetidinoner som er anvendbare som hypokolesterolemiske midler
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
AU6703786A (en) New medical use of tetrahydrocarbazolones derivative
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
CA2219050A1 (fr) Derives de polyamine comme agents radioprotecteurs
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
IS1664B (is) Ný aðferð við að framleiða útskipt 4-fenýl-4-píperídínkarboxamíð sem hefur bæði staðbundin deyfandiog kvalastillandi áhrif
RU94045156A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования преждевременного полового созревания
RU94045280A (ru) Средство для ингибирования патологических состояний молочных желез
RU2091378C1 (en) 7-acyl-3-substituted carbamoylhydroxycephems, methods of their synthesis, substituted carbamoylhydroxy-3-cephems, methods of their synthesis and antibacterial composition
AU2585188A (en) New N-(23-vinblastinoyl) derivatives of 1-aminomethyl- phosphonic acid, processes for preparing them and pharmaceutical compositions containing them
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
HUP9802736A2 (hu) 1,4-Dihidropiridin-származékok alkalmazása artériafal ateroszklerózisos degradálódásának megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
TW261605B (fr)
AU4944899A (en) New pharmaceutically active compounds
AU6902800A (en) Pyridomorphinans and use thereof
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
EE03518B1 (et) Farmatseutiline kompositsioon ja selle kasutamine
AU3409795A (en) Methods for bone healing and fracture repair
AU2788995A (en) Fungicidal mixtures
AU667294B2 (en) Cyclopentane ether derivatives, methods for preparing them and their use in pharmaceuticals
DK549085A (da) 3-aminopropoxyphenylderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater, som indeholder disse derivater